Amy Graham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amy Graham has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Daniel J. Lindner
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
1 shared publication - Denis R. Burger
CytoDyn Inc., 1111 Main Street, Vancouver, WA, United States, 98660, USA
1 shared publication - Judith A. Drazba
Imaging Core, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, United States, 44195, USA
1 shared publication - Kathryn Guinta
Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, 9500 Euclid Avenue, NE-6, Cleveland, OH, United States, 44195, USA
1 shared publication - Patricia Parsons-Wingerter
NASA Glenn Research Center, Cleveland, OH, United States, 44126, USA
1 shared publication - Richard G. Pestell
Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Wynnewood, USA
1 shared publication
Latest Publications
- Open Access
- 6 November 2025
- Published by MDPI AG in Preprints.org
Leronlimab Inhibits Colon Carcinoma Metastasis in a Humanized Mouse Xenograft Model
Leronlimab, a humanized monoclonal antibody directed to the CCR5 receptor, demonstrated anti-tumor activity in humanized NSG mouse models of both heterotopic and orthotopic SW480 human colon carcinoma. The anti-tumor effect was lost in non-humanized mice, suggesting a critical role for engrafted human leukocytes. Development of xGVHD was delayed in both tumor-bearing and non-tumor-bearing mice that had been treated with leronlimab. Leronlimab induced human CD4+CD25+ cells in the peripheral blood of tumor-bearing (1.5-fold increase, p=0.016) and non-tumor-bearing animals (2.2-fold, p=0.0038). Leronlimab reduced CD4+CD25- cells (1.84-fold reduction, p=0.033). In the orthotopic colon cancer model, lung metastatic burden was decreased ~87% in leronlimab-treated mice compared to IgG-treated animals (p=0.012). Blockade of CCR5 signaling reduced peri-tumoral vessel formation feeding the tumor, 62% (p=0.013). As CD4+CD25+ T cells, play a crucial role in immune checkpoint inhibitor (ICI) responses we assessed CCR5/immune checkpoint gene expression in human colon cancer. CCR5 and its ligands were overexpressed in human colon cancer, correlating with increased immune checkpoint gene expression in both microsatellite stable (MSS) and instable (MSI) patients.
- 6 November 2025
- Published by MDPI AG in Preprints.org
Open AccessLeronlimab Inhibits Colon Carcinoma Metastasis in a Humanized Mouse Xenograft Model
Leronlimab, a humanized monoclonal antibody directed to the CCR5 receptor, demonstrated anti-tumor activity in humanized NSG mouse models of both heterotopic and orthotopic SW480 human colon carcinoma. The anti-tumor effect was lost in non-humanized mice, suggesting a critical role for engrafted human leukocytes. Development of xGVHD was delayed in both tumor-bearing and non-tumor-bearing mice that had been treated with leronlimab. Leronlimab induced human CD4+CD25+ cells in the peripheral blood of tumor-bearing (1.5-fold increase, p=0.016) and non-tumor-bearing animals (2.2-fold, p=0.0038). Leronlimab reduced CD4+CD25- cells (1.84-fold reduction, p=0.033). In the orthotopic colon cancer model, lung metastatic burden was decreased ~87% in leronlimab-treated mice compared to IgG-treated animals (p=0.012). Blockade of CCR5 signaling reduced peri-tumoral vessel formation feeding the tumor, 62% (p=0.013). As CD4+CD25+ T cells, play a crucial role in immune checkpoint inhibitor (ICI) responses we assessed CCR5/immune checkpoint gene expression in human colon cancer. CCR5 and its ligands were overexpressed in human colon cancer, correlating with increased immune checkpoint gene expression in both microsatellite stable (MSS) and instable (MSI) patients.